$599

Zealand completes 2nd Ph3 pivotal rescue trial for dasiglucagon

Zealand reported completion of the second Ph3 dasiglucagon pivotal trial for the treatment of severe hypoglycemia, slightly ahead of previous guidance. Results of the trial, which included 156 T1DM subjects, are now anticipated in Q3 2018.

This content is for Read Less members only.
Register
Already a member? Log in here